Standard lipid panels measure total cholesterol, HDL, LDL, and triglycerides. For the general population, these four numbers provide a reasonable cardiovascular risk assessment. For AAS users, this panel is dangerously incomplete.
The problem is that AAS universally suppress HDL. This is a pharmacological class effect — it happens with virtually every compound and at virtually every dose. A low HDL reading tells you something about your compound choice, but it tells you almost nothing about your actual cardiovascular risk.
💡If you only look at HDL, you will spend your entire cycle worrying about a number that was going to drop anyway. You will miss the markers that actually predict cardiovascular outcomes.
Cardiovascular Markers Under AAS
Here are the five markers every AAS user needs to understand for cardiovascular risk assessment — and which ones actually matter:
HDL Cholesterol
LDL Cholesterol
ApoB (Apolipoprotein B)
Triglycerides
Lp(a) — Lipoprotein(a)
Why LDL Alone Is Not Enough
Understanding ApoB with a Simple Analogy
Imagine cholesterol particles as trucks delivering goods (cholesterol) to your body. The LDL test measures the total cargo carried by all trucks. The ApoB test counts the number of trucks on the road.
A few large trucks carrying lots of cargo (high LDL, low ApoB) = manageable traffic. Many small trucks carrying the same total cargo (normal LDL, high ApoB) = traffic jam. The number of trucks matters more than the total cargo, because more trucks means more opportunities for them to crash into your artery walls.
Low Risk Profile
LDL: 150 mg/dL, ApoB: 85 mg/dL. Your LDL looks high, but you have few atherogenic particles. Those particles are large and fluffy — less likely to penetrate arterial walls.
High Risk Profile
LDL: 120 mg/dL, ApoB: 145 mg/dL. Your LDL looks borderline, but you have many small, dense particles. Each one is a tiny threat. ApoB reveals the true risk that LDL hides.
Standard vs. Complete Lipid Panel for AAS Users
| Marker | Standard Panel | Complete Panel |
|---|---|---|
| Total Cholesterol | Measured | Measured |
| HDL | Measured | Measured |
| LDL (calculated) | Measured | Measured |
| Triglycerides | Measured | Measured |
| ApoB | Not measured | Measured — the key risk indicator |
| Lp(a) | Not measured | Measured — genetic risk factor |
| ApoA1 | Not measured | Measured — HDL counterpart |
| LDL Particle Count | Not measured | Measured — direct atherogenic load |
| ApoB / ApoA1 Ratio | Not calculated | Calculated — strong predictor of risk |
The ApoB / ApoA1 Ratio
ApoA1 is the primary protein in HDL particles. The ratio of ApoB to ApoA1 is one of the strongest independent predictors of cardiovascular risk — stronger than LDL, stronger than HDL, and stronger than total cholesterol.
A ratio below 0.7 is considered low risk. Above 1.0 indicates elevated risk. Many AAS users on blast will have ratios between 1.0 and 1.5. This is useful information — but it must be interpreted alongside other markers, not in isolation.
ApoB > 130 mg/dL Requires Attention
How to Interpret Your Lipid Panel Under AAS
Here is how to interpret your cardiovascular markers under AAS — combining all the pieces into practical scenarios:
Low HDL + Normal ApoB — The Common Pattern
Low HDL + Elevated ApoB — The Real Signal
Low HDL + Elevated ApoB + Elevated Lp(a) — Highest Concern
Normal HDL (Uncommon Under AAS) — Favorable Genetics
Practical Lipid Management for AAS Users
If your lipid profile needs attention, here are the most effective interventions, ranked by impact:
Compound Selection
The single biggest lever. Some compounds are far more lipid-toxic than others. Testosterone and nandrolone are relatively mild on lipids. Trenbolone, Anadrol, and Winstrol are the worst offenders. Choosing compounds wisely is the first line of defense.
Dose Reduction
Lipid impact is dose-dependent. Dropping from 500 mg to 300 mg per week often produces meaningful improvements in HDL and ApoB. The marginal gains from higher doses may not be worth the lipid cost.
Cardiovascular Support
Daily cardio (30+ minutes), omega-3 fatty acids (3-4g/day EPA+DHA), a Mediterranean-style diet, and limiting saturated fats all help. These interventions are not as powerful as compound changes, but every point of ApoB reduction matters.
Medication (When Needed)
Ezetimibe, telmisartan, and in some cases statins are options for managing ApoB elevation under AAS. These require a doctor's prescription but are well-tolerated and effective. Do not hesitate to explore this path if ApoB stays elevated despite compound adjustments.